FNCH FINCH THERAPEUTICS GROUP INC

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences:

  • Jefferies London Healthcare Conference

    Wednesday, November 16, 2022 at 10:55 am GMT

    Corporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer
  • Evercore ISI HealthCONx Conference

    Thursday, December 1, 2022 at 11:20 am ET

    Fireside chat with Mark Smith, PhD, Chief Executive Officer

Live webcasts of both events will be available under the ‘’ section of the Finch website. Replays of the webcasts will be available on Finch’s website for approximately 30 days after each event.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is exploring strategic options to potentially advance the development of its pre-clinical candidates FIN-524 for ulcerative colitis and FIN-525 for Crohn's disease and its pre-clinical program in autism spectrum disorder. Finch routinely posts information that may be important to its investors on its website at . Finch encourages investors to consult the “Investors & News” section of its website regularly.

Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:

Stephen Jasper

Gilmartin Group

(858) 525-2047

Media Contact:

Jenna Urban

Berry & Company Public Relations

(212) 253-8881



EN
09/11/2022

Underlying

FNCHFINCH THERAPEUTICS GROUP INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FINCH THERAPEUTICS GROUP INC

 PRESS RELEASE
Free
FNCH FINCH THERAPEUT...

Finch Announces Delisting from Nasdaq and SEC Deregistration

Finch Announces Delisting from Nasdaq and SEC Deregistration BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Nasdaq: FNCH) (“Finch” or the “Company”), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC (“Nasdaq”) of its intent to delist the Company’s common stock, par value $0.001 per share (the “Common Stock”), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securitie...

October 21, 2024 1 EN
 PRESS RELEASE
Free
FNCH FINCH THERAPEUT...

Finch Announces Reverse Stock Split of Common Stock

Finch Announces Reverse Stock Split of Common Stock BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch’s Annual Meeting of Stockholders held on June 8, 2023. The ...

June 9, 2023 1 EN
 PRESS RELEASE
Free
FNCH FINCH THERAPEUT...

Finch Therapeutics Reports First Quarter 2023 Financial Results and Pr...

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. “Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-s...

May 10, 2023 1 EN
 PRESS RELEASE
Free
FNCH FINCH THERAPEUT...

Finch Therapeutics Announces Executive Leadership Transitions

Finch Therapeutics Announces Executive Leadership Transitions Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ...

April 25, 2023 1 EN
 PRESS RELEASE
Free
FNCH FINCH THERAPEUT...

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Coli...

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women’s Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulce...

April 18, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch